Form 4: Rigel Pharmaceuticals Director Receives Stock Grant

Director Anthony Gregg LaPointe acquired 5,750 shares of Rigel Pharmaceuticals common stock via a restricted stock unit award.

Summary

• Director Anthony Gregg LaPointe was granted 5,750 restricted stock units (RSUs).
• The shares were acquired at a price of $0 per share as part of a compensation award.
• Following this transaction, the director's total beneficial ownership of common stock increased to 18,250 shares.
• The RSUs are scheduled to vest on the date prior to the company's next annual meeting, contingent upon continued board service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial outlook.

Positives

• Increased equity alignment between the director and shareholders.

Negatives

• None identified.

Risks

• Vesting of the award is subject to the director's continuous service on the Board of Directors.

Future Outlook

The restricted stock units will fully vest on the day prior to the company's next annual meeting, provided the director remains in service.

Industry Context

StockSavvy.ai notes that director equity grants are standard corporate governance practices in the biotechnology sector to ensure board members maintain a vested interest in long-term company performance.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is consistent with standard compensation practices for mid-cap pharmaceutical companies.
• The vesting schedule tied to the annual meeting is a common retention mechanism for board members.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon the eventual vesting and issuance of the shares.

Next Steps

• Vesting of the 5,750 RSUs prior to the next annual meeting.

Key Dates

Keywords

Rigel Pharmaceuticals, RIGL, Director Compensation, Insider Transaction, Restricted Stock Units, SEC Form 4